NKTR and renal cell adenocarcinoma: In patients with metastatic melanoma and renal cell cancer, including those who had failed PD-1 CPI therapy, NKTR-214 monotherapy enhanced peripheral and intratumoral CD8+ T-cell proliferation and numbers without increasing intratumoral Tregs, and without causing serious toxicity16.